Abstract Appendix for PPC 2018 Poster Abstracts Document supplémentaire pour les résumés des affiches de la CPP 2018


Appendix Figure: Information card developed to support the preferred practice of patients/families returning medications to a pharmacy



Supplementary material for Hyland B, Fan M, Hamilton M, Reding R, Tribovich P. Informing patients and families about storage and disposal of opioids [abstract]. Can J Hosp Pharm. 2018;71(1):61.

For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact *CJHP* at publications@cshp.ca

Appendix Figure: Screen capture from database developed in-house to capture antimicrobial stewardship interventions at the patient level.



Supplementary material for Patel S, Patel M. An innovative in-house developed Access® database to capture and analyze antimicrobial stewardship interventions [abstract]. Can J Hosp Pharm. 2018;71(1):69.

Appendix Table. Results

	Patients 65-79 Years Old (N=129; Cases=83, Controls=46)	Patients ≥ 80 Years Old (N=181; Cases=101, Controls=80)	Patients ≥ 65 Years Old (N=310; Cases=184, Controls=126)
Pre-Test Probability of Bacteremia (%)	64	56	59
Sensitivity (%)	82	79	80
Specificity (%)	93	89	90
Accuracy (%)	86	83	85
Positive Predictive Value and Post-Test Probability (%)	96	90	92
Negative Predictive Value	74	77	76
Negative Post-Test Probability (%)	26	23	24
Positive Likelihood Ratio	13	7	8
Negative Likelihood Ratio	0.19	0.23	0.22
False Positive Rate (%)	7	11	10
False Negative Rate (%)	18	21	20

Supplementary material for Walker SAN, Peragine C, Ma N, Bannerman H, Elligsen M, Palmay L, et al. Validation of a screening tool to assist in the early identification of bloodstream infection in older patients [abstract]. Can J Hosp Pharm. 2018;71(1):78.

Appendix Table. Evaluating Preparedness and Interest

 Please describe the extent to which you feel prepared to assess the safety of antibiotics for the penicillin-allergic patient. 					
"Very Prepared" or "Somewhat Prepared"		"Somewhat Unprepared" or "Very Unprepared"			
PRE: 375/580 (64.7%)	POST: 2	220/281 (78.3%)	PRE: 205/580 (35.3%) POST:		POST: 61/281 (21.7%)
2. Please describe the extent to which you feel prepared to determine if a patient has a history of an allergic reaction that was severe or life –threatening.					
"Very Prepared" or "Some	"Very Prepared" or "Somewhat Prepared"		"Somewhat Unprepared" or "Very Unprepared"		
PRE: 448/580 (77.2%)	POST: 2	235/281 (83.6%)	PRE: 132/580 (22.8%)		POST: 46/281 (16.3%)
3. How interested are you in using the new ASC Guideline for the Management of Penicillin and Beta-Lactam Allergies?					
"Very Interested" or "Somewhat Interested"	"Neither interested"		d	"Somewhat Disinterested" or "Very disinterested"	
181/215 (84.2%)		25/2015 (11.6%)	9/215 (4.2%)		.2%)
4. Has your practice changed as a result of reviewing the ASC Guideline for the Management of Penicillin and Beta-Lactam Allergies or related educational interventions?					
	"Yes"		"No"		
	99/214 (46.3%)		115/214 (53.7%)		

Supplementary material for Landry D, MacLaggan T. Development and implementation of a provincial beta-lactam allergy management initiative [abstract]. Can J Hosp Pharm. 2018;71(1):79-80.

Appendix Table. Multiple Linear Regression of Cefazolin Percent Remaining

	Unstandardized Coefficients		Standardized Coefficients		Significance
Model	В	Std. Error	Beta	t-value	(p value)
Dependent Variable: Percent Remaining					
Constant	99.359	1.378		72.083	.000
Study Day	149	.034	343	-4.354	.000
Lab	.601	.193	.308	3.119	.002
Manufacturer	.164	.225	.083	.729	.467
Temperature	-4.339	.596	504	-7.275	.000
Diluent	1.047	.584	.157	1.791	.075
Concentration	020	.011	197	-1.869	.063
Container	021	.595	004	036	.971

Supplementary material for Xu Y, Walker SE. Influence of manufacturer on cefazolin stability [abstract]. Can J Hosp Pharm. 2018;71(1):81-2.

Appendix Table. Themes from Interprofessional Perspectives on cpKPI

Theme (# of Participants Contributing to Theme (n=92)	Sub-Theme	# of Participants Contributing Sub-Theme (n=92)
1) cpKPls are important to support the need for pharmacists and their patient care role (65)	1a) Individual cpKPIs are important to support the need for pharmacists and their patient care role	32
	1b) cpKPls are important to create a benchmark for pharmacists	20
	1c) 3. Measuring cpKPls is important to support the need for pharmacists in their patient care role.	9
	1d) cpKPI-related care can reduce the patient care activity workload for other health care professionals	4
2) There is a shared inter-professional responsibility for delivering cpKPI-related care (28)	2a) cpKPI-related care is inter-professional and may not reflect just the pharmacist's contributions	28
3) There are challenges to measuring cpKPls (24)	3a) There are limitations to the interpretation of cpKPI services when using the measurement of proportions	13
	3b) It may be practically difficult to measure individual cpKPIs.	11
4) cpKPls should be tailored and prioritizedfor patient populations that	4a) There is a need to prioritize patients who benefit from certain cpKPI services.	15
would benefit the most from its implementation (28)	4b) cpKPIs should be tailored based on hospital setting and type of patients encountered	13
5) The pharmacist's care plan needs to be documented, shared, and integrated with the team's care plan (6)	5a) Pharmaceutical care plans should be integrated with an interprofessional team care plan	6
6) There needs to be collaboration with community pharmacists for continuity of cpKPIs post-discharge (14)	6a) Inpatient pharmacists should collaborate with community pharmacists to ensure smooth transition of care after discharge	14
7) Improvement suggestions for cpKPI descriptions (26)	7a) Individual cpKPI descriptions require further clarification	26
8) cpKPls are interdependent and overlapping care processes (18)	8a) Individual cpKPIs are not mutually exclusive but rather are overlapping care processes	18

Supplementary material for Fernandes O, Raymond C, Mourao D, Meade A, Toombs K, Slobodan J, et al. Qualitative thematic analysis of interprofessional perspectives on clinical pharmacy key performance indicators [abstract]. *Can J Hosp Pharm.* 2018;71(1):85.